Dr. John Cush RheumNow
2 years 4 months ago
#RNL2024 @RheumNow
@Bweber04
Asymptomatic Lupus has higher rate of atherosclerosis at all age grps
35-44 yo F with SLE: 50X increased risk of MI compared to healthy pts in Framingham
RA pts at 1.5x risk of CVD https://t.co/wL4U8Gh5JM
RheumNow Live 2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in Rheumatoid Arthritis."
Dr. John Cush RheumNow
2 years 4 months ago
#RNL2024
ASCVD Risk Calculators underestimate risk in patients of RA
Inflammatory disease was added as a "risk enhancer" in 2019 update
"A low ASCVD and/or absence of symptoms may be not be reassuring" https://t.co/Cz1LRda9xx
The large vessel vasculitis, Takayasu arteritis (TAK), carries a significant morbid risk and a cohort analysis shows these patients are also at high risk of serious infection with resultant higher risk of death.
Dr. John Cush RheumNow
2 years 4 months ago
13 Risk Factors for RA-associated Interstitial Lung Disease (ILD)
ILD is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.
https://t.co/oqb37RWPuZ https://t.co/tp3qBh1wRC
Dr. John Cush RheumNow
2 years 4 months ago
Pearl: Three "S" Rule (Smoking, Seropositivity, Sex/Male): if present the risk of RA-UIP (ILD) goes up nearly 13 fold (ACR23 Abstract 1269) https://t.co/heiTtarS1Y https://t.co/EkHbmMgIEC
Dr. John Cush RheumNow
2 years 4 months ago
RCT 302 Dupuytren contracture pts Rx w/ Surgery (n 101), needle fasciotomy (101), or collagenase injx (100). 292 & 284 completed; Success (>50% improved) @3 mos was same: 71%, 73% & 73%. @ 2 yrs, surgery was superior (78% vs. 50% or 65%) https://t.co/K74p1xpnZx https://t.co/xaC4pdPSFQ
Dr. John Cush RheumNow
2 years 4 months ago
JAMA: Industry Payments to Physicians ($12.13 billion 2013-22)
1 Ortho: $1,360,744,428
2 Neuro: $1,322,668,751
3 Cardio: $1,293,613,594
4 Heme/onc: $825,799,685
5 Int medicine: $588,249,423
6 Endo: $546,513,674
7 FP: $479,105,369
8 Rheum: $464,858,022
https://t.co/GCWchn9IMz https://t.co/6sRwOWm83y
Dr. John Cush RheumNow
2 years 4 months ago
soluble Fms‐like tyrosine kinase‐1 (sFlt-1)/placental growth factor (PlGF) ratio, biomarkers of placental function and adverse pregnancy outcomes. Study of 158 RA pts, 1/2 on TNFi during Preg. TNFi assoc w/ incr birthweight; no effx on sFlt‐1 & PlGF https://t.co/JFvDxrTAfr https://t.co/CRxSEbm2Ru
Dr. John Cush RheumNow
2 years 4 months ago
CDC surveillance data 2019–2021 identified cases:
- 59,655 coccidioidomycosis
- 3,595 histoplasmosis
- 719 blastomycosis (unusually high fatality rate in 2021 of 17%; typically 8%–10%) https://t.co/cDC0nuZLsb https://t.co/Q4QkNtNvJc
Dr. John Cush RheumNow
2 years 4 months ago
FDA Curriculum and Toolkit on Biosimilars for educators; Fact sheets on:
- Biologicals, Biosimilars & InterchangeableProducts
- Generics & Biosimilars
- Manufacturing & Variation
- Biosimilar Regulatory Approval Pathway https://t.co/bHYFPb8VxU https://t.co/bA8I567H8U
The Annals of Rheumatic Disease reports that mortality risk in psoriatic arthritis (PsA) is about 10% higher than in the general population, primarily from excess comorbidity and with increased risks in women, with longer disease durations.
Dr. John Cush RheumNow
2 years 4 months ago
There is world wide variability the prevalence of #PsA - the global prevalence=112 per 100K adults; and is more common in Europe (207/100K) and North America (64/100K) compared with Asia (37/100K) and South America https://t.co/UY25S00w26 https://t.co/AZMbZ3hG2c
